Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell ...
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data under ...
SAN DIEGO, March 28, 2022 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem ...
The Shin Kaneko laboratory at CiRA has developed a method to generate CAR-T cells from iPS cells (iCAR-T cells) that possess vastly improved anti-tumor activity in a mouse model of solid tumors. In ...
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients ...
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune ...
9:00am-4:00pm Monday to Friday Audience: Faculty, Students, Graduate Students, PostDoc Workshop Fee: $975 (CU Boulder Researchers) https://www.colorado.edu/center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results